UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: January 2018 (Report No. 1)
Commission file number: 001-35932
ARCTURUS THERAPEUTICS LTD.
(Translation of registrant’s name into English)
10628 Science Center Drive, Suite 200
San Diego, California 92121
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): _____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): _____
Effective January 23, 2018, Orli Tori resigned as a member of the board of directors of Arcturus Therapeutics Ltd. (the “Registrant”). Ms. Tori’s resignation was for personal reasons and not due to any disagreement with the Registrant.
This Form 6-K is incorporated by reference into the Registration Statements on Form F-3 (File No. 333- 209960) and Form S-8 (File No. 333-194875, File No. 333-202394, File No. 333-209947, File No. 333-217556 and File No. 333-221830) of the Registrant, filed with the SEC, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Arcturus Therapeutics Ltd. | |||
Dated: January 24, 2018 | |||
By: |
/s/ Stuart Collinson | ||
Name: Stuart Collinson Title: Executive Chairman |